Grifols SA, Barcelona Stock Price, News & Analysis (NASDAQ:GRFS)

$22.47 -0.25 (-1.10 %)
(As of 02/23/2018 01:25 PM ET)
Previous Close$22.47
Today's Range$22.38 - $22.80
52-Week Range$17.24 - $25.18
Volume337,100 shs
Average Volume468,952 shs
Market Capitalization$5.94 billion
P/E Ratio21.04
Dividend Yield1.25%
Beta1.08

About Grifols SA, Barcelona (NASDAQ:GRFS)

Grifols SA, Barcelona logoGrifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

Receive GRFS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GRFS
CUSIPN/A
Phone34-93-571-2200

Debt

Debt-to-Equity Ratio1.69%
Current Ratio3.17%
Quick Ratio1.39%

Price-To-Earnings

Trailing P/E Ratio21.04
Forward P/E Ratio18.88
P/E Growth1.52

Sales & Book Value

Annual Sales$4.48 billion
Price / Sales3.42
Cash Flow$1.32 per share
Price / Cash16.99
Book Value$6.04 per share
Price / Book3.72

Profitability

Trailing EPSN/A
Net Income$603.60 million
Net Margins13.16%
Return on Equity18.08%
Return on Assets6.22%

Miscellaneous

Employees14,877
Outstanding Shares682,820,000

Grifols SA, Barcelona (NASDAQ:GRFS) Frequently Asked Questions

What is Grifols SA, Barcelona's stock symbol?

Grifols SA, Barcelona trades on the NASDAQ under the ticker symbol "GRFS."

How often does Grifols SA, Barcelona pay dividends? What is the dividend yield for Grifols SA, Barcelona?

Grifols SA, Barcelona announced a semiannual dividend on Friday, May 26th. Stockholders of record on Thursday, June 1st will be given a dividend of $0.122 per share on Thursday, June 8th. This represents a dividend yield of 1.54%. The ex-dividend date of this dividend is Tuesday, May 30th. View Grifols SA, Barcelona's Dividend History.

When did Grifols SA, Barcelona's stock split? How did Grifols SA, Barcelona's stock split work?

Shares of Grifols SA, Barcelona split on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were distributed to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of Grifols SA, Barcelona stock prior to the split would have 200 shares after the split.

Who are some of Grifols SA, Barcelona's key competitors?

Who owns Grifols SA, Barcelona stock?

Grifols SA, Barcelona's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include ARTISAN PARTNERS LIMITED PARTNERSHIP (3.60%), Alliancebernstein L.P. (1.33%), Bank of New York Mellon Corp (0.90%), Vaughan Nelson Investment Management L.P. (0.42%), BlackRock Inc. (0.29%) and First Trust Advisors LP (0.28%). View Institutional Ownership Trends for Grifols SA, Barcelona.

Who sold Grifols SA, Barcelona stock? Who is selling Grifols SA, Barcelona stock?

Grifols SA, Barcelona's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, BlackRock Inc., GABELLI & Co INVESTMENT ADVISERS INC., Gabelli Funds LLC, Arrowstreet Capital Limited Partnership, Citadel Advisors LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Grifols SA, Barcelona.

Who bought Grifols SA, Barcelona stock? Who is buying Grifols SA, Barcelona stock?

Grifols SA, Barcelona's stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Engadine Partners LLP, Two Sigma Advisers LP, Two Sigma Investments LP, Vaughan Nelson Investment Management L.P., First Trust Advisors LP, Kornitzer Capital Management Inc. KS and Jefferies Group LLC. View Insider Buying and Selling for Grifols SA, Barcelona.

How do I buy Grifols SA, Barcelona stock?

Shares of Grifols SA, Barcelona can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Grifols SA, Barcelona's stock price today?

One share of Grifols SA, Barcelona stock can currently be purchased for approximately $22.47.

How big of a company is Grifols SA, Barcelona?

Grifols SA, Barcelona has a market capitalization of $5.94 billion and generates $4.48 billion in revenue each year. Grifols SA, Barcelona employs 14,877 workers across the globe.

How can I contact Grifols SA, Barcelona?

Grifols SA, Barcelona's mailing address is AVINGUDA DE LA GENERALITAT 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 34-93-571-2200 or via email at [email protected]


MarketBeat Community Rating for Grifols SA, Barcelona (GRFS)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  135 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  328
MarketBeat's community ratings are surveys of what our community members think about Grifols SA, Barcelona and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Grifols SA, Barcelona (NASDAQ:GRFS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.752.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Grifols SA, Barcelona (NASDAQ:GRFS) Consensus Price Target History

Price Target History for Grifols SA, Barcelona (NASDAQ:GRFS)

Grifols SA, Barcelona (NASDAQ:GRFS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/31/2017CitigroupInitiated CoverageBuy -> BuyN/AView Rating Details
7/4/2017Bank of AmericaReiterated RatingBuyMediumView Rating Details
6/30/2017Goldman Sachs GroupDowngradeBuy -> NeutralLowView Rating Details
3/30/2017JPMorgan Chase & Co.UpgradeNeutral -> OverweightHighView Rating Details
6/6/2016Morgan StanleyReiterated RatingSellN/AView Rating Details
3/17/2016NomuraInitiated CoverageBuyN/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Grifols SA, Barcelona (NASDAQ:GRFS) Earnings History and Estimates Chart

Earnings by Quarter for Grifols SA, Barcelona (NASDAQ:GRFS)

Grifols SA, Barcelona (NASDAQ GRFS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017$0.29$0.29$1.24 billionViewN/AView Earnings Details
7/28/2017Q2 2017$0.28$0.27$1.19 billion$1.24 billionViewN/AView Earnings Details
5/3/2017Q1 2017$0.27$0.26$1.14 billion$1.13 billionViewN/AView Earnings Details
2/28/2017Q4 2016$0.26$1.19 billionViewN/AView Earnings Details
11/8/2016Q3 2016$0.28$1.12 billionViewN/AView Earnings Details
7/28/2016Q2 2016$0.27$0.27$1.19 billion$1.12 billionViewN/AView Earnings Details
5/5/2016Q1 2016$0.24$0.22$1.04 billion$1.06 billionViewN/AView Earnings Details
11/4/2015Q3 2015$0.22$0.23$1.01 billion$1.08 billionViewN/AView Earnings Details
7/30/2015Q2 2015$0.23$0.22$1.10 billionViewN/AView Earnings Details
5/7/2015Q1 2015$0.24$0.25$972.80 million$1.02 billionViewN/AView Earnings Details
2/26/2015Q4 2014$0.29$0.27$1.04 billionViewN/AView Earnings Details
10/31/2014Q3 2014$0.26$0.22$1.04 billion$1.10 billionViewN/AView Earnings Details
7/30/2014Q2 2014$0.28$0.20$1.16 billion$1.09 billionViewN/AView Earnings Details
5/6/2014Q1 2014$0.28$0.25$1.11 billionViewN/AView Earnings Details
2/20/2014Q4 2013$0.15$923.39 millionViewN/AView Earnings Details
11/5/2013Q3 2013$0.17$881.88 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.18$924.58 millionViewN/AView Earnings Details
5/2/2013Q1 2013$0.18$903.10 millionViewN/AView Earnings Details
2/28/2013Q4 2012$0.10ViewN/AView Earnings Details
10/30/2012Q3 2012$0.12ViewN/AView Earnings Details
7/31/2012Q2 2012$0.11ViewN/AView Earnings Details
5/11/2012Q1 2012$0.15ViewN/AView Earnings Details
2/28/2012Q4 2011$0.05ViewN/AView Earnings Details
11/14/2011Q3 2011$0.08ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Grifols SA, Barcelona (NASDAQ:GRFS) Earnings Estimates

2018 EPS Consensus Estimate: $1.27
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.29$0.29$0.29
Q2 20181$0.33$0.33$0.33
Q3 20181$0.31$0.31$0.31
Q4 20181$0.34$0.34$0.34
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Grifols SA, Barcelona (NASDAQ:GRFS) Dividend Information

Most Recent Dividend:6/8/2017
Annual Dividend:$0.28
Dividend Yield:1.25%
Payout Ratio:23.53% (Based on This Year's Estimates)
21.54% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Grifols SA, Barcelona (NASDAQ:GRFS)

Grifols SA, Barcelona (NASDAQ:GRFS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/26/2017semiannual$0.121.54%5/30/20176/1/20176/8/2017
11/22/2016$0.1512/5/201612/7/201612/7/2016
5/31/2016$0.116/2/20166/6/20166/6/2016
12/1/2015$0.3012/10/201512/14/201512/14/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Grifols SA, Barcelona (NASDAQ GRFS)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Grifols SA, Barcelona (NASDAQ GRFS) News Headlines

Source:
DateHeadline
Technical Perspectives on Biotech Stocks -- Grifols, Heat Biologics, Hemispherx Biopharma, and iBioTechnical Perspectives on Biotech Stocks -- Grifols, Heat Biologics, Hemispherx Biopharma, and iBio
www.bizjournals.com - February 8 at 8:39 AM
VBI Vaccines (VBIV) & Grifols SA, Barcelona (GRFS) Head-To-Head AnalysisVBI Vaccines (VBIV) & Grifols SA, Barcelona (GRFS) Head-To-Head Analysis
www.americanbankingnews.com - February 6 at 11:06 PM
BRIEF-Grifols Receives FDA Approval For New Formulation Of Its Rabies Virus TreatmentBRIEF-Grifols Receives FDA Approval For New Formulation Of Its Rabies Virus Treatment
www.reuters.com - February 6 at 4:10 PM
Grifols HyperRAB® (rabies immune globulin ) 300 IU/mL Receives FDA Approval to Treat Patients Exposed to Rabies Virus InfectionGrifols HyperRAB® (rabies immune globulin ) 300 IU/mL Receives FDA Approval to Treat Patients Exposed to Rabies Virus Infection
finance.yahoo.com - February 6 at 4:10 PM
Grifols SA, Barcelona (GRFS) Receives Consensus Rating of "Hold" from BrokeragesGrifols SA, Barcelona (GRFS) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 4 at 3:30 AM
BRIEF-Grifols Sees Positive Impact Of 90 Mln Euros In Q4 After Revaluation Of US AssetsBRIEF-Grifols Sees Positive Impact Of 90 Mln Euros In Q4 After Revaluation Of US Assets
www.reuters.com - January 30 at 9:58 AM
BidaskClub Lowers Grifols SA, Barcelona (GRFS) to HoldBidaskClub Lowers Grifols SA, Barcelona (GRFS) to Hold
www.americanbankingnews.com - January 20 at 10:28 AM
Grifols SA, Barcelona (GRFS) Receives Average Rating of "Hold" from BrokeragesGrifols SA, Barcelona (GRFS) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 10 at 3:08 AM
Grifols SA, Barcelona (GRFS) Upgraded to "Hold" by Zacks Investment ResearchGrifols SA, Barcelona (GRFS) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - January 4 at 11:52 PM
First Week of August 17th Options Trading For Grifols SA - NasdaqFirst Week of August 17th Options Trading For Grifols SA - Nasdaq
www.nasdaq.com - January 3 at 5:11 PM
Stocks With Rising Relative Price Strength: GrifolsStocks With Rising Relative Price Strength: Grifols
finance.yahoo.com - January 3 at 5:11 PM
Grifols SA, Barcelona (GRFS) versus Trillium Therapeutics (TRIL) Financial ComparisonGrifols SA, Barcelona (GRFS) versus Trillium Therapeutics (TRIL) Financial Comparison
www.americanbankingnews.com - January 2 at 9:14 PM
Grifols SA, Barcelona (GRFS) Upgraded by BidaskClub to HoldGrifols SA, Barcelona (GRFS) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - December 28 at 4:56 PM
Comparing Tetralogic Pharmaceuticals (TLOG) and Grifols SA, Barcelona (GRFS)Comparing Tetralogic Pharmaceuticals (TLOG) and Grifols SA, Barcelona (GRFS)
www.americanbankingnews.com - December 28 at 9:28 AM
BidaskClub Upgrades Grifols SA, Barcelona (GRFS) to "Sell"BidaskClub Upgrades Grifols SA, Barcelona (GRFS) to "Sell"
www.americanbankingnews.com - December 24 at 8:15 AM
ETFs with exposure to Grifols SA : December 19, 2017ETFs with exposure to Grifols SA : December 19, 2017
finance.yahoo.com - December 19 at 5:09 PM
Reviewing Mateon Therapeutics (MATN) & Grifols SA, Barcelona (GRFS)Reviewing Mateon Therapeutics (MATN) & Grifols SA, Barcelona (GRFS)
www.americanbankingnews.com - December 17 at 5:32 AM
Comparing Anavex Life Sciences (AVXL) and Grifols SA, Barcelona (GRFS)Comparing Anavex Life Sciences (AVXL) and Grifols SA, Barcelona (GRFS)
www.americanbankingnews.com - December 16 at 1:30 AM
Grifols SA : GRFS-US: Dividend Analysis : December 04th, 2017 (record date) : By the numbers : December 11, 2017Grifols SA : GRFS-US: Dividend Analysis : December 04th, 2017 (record date) : By the numbers : December 11, 2017
finance.yahoo.com - December 11 at 5:20 PM
BidaskClub Lowers Grifols SA, Barcelona (GRFS) to Strong SellBidaskClub Lowers Grifols SA, Barcelona (GRFS) to Strong Sell
www.americanbankingnews.com - December 9 at 9:56 AM
Grifols SA, Barcelona (GRFS) vs. Mateon Therapeutics (MATN) Head-To-Head ContrastGrifols SA, Barcelona (GRFS) vs. Mateon Therapeutics (MATN) Head-To-Head Contrast
www.americanbankingnews.com - December 8 at 9:52 AM
Analyzing Tetralogic Pharmaceuticals (TLOG) & Grifols SA, Barcelona (GRFS)Analyzing Tetralogic Pharmaceuticals (TLOG) & Grifols SA, Barcelona (GRFS)
www.americanbankingnews.com - December 7 at 11:42 AM
ETFs with exposure to Grifols SA : December 5, 2017ETFs with exposure to Grifols SA : December 5, 2017
finance.yahoo.com - December 5 at 5:06 PM
Head-To-Head Analysis: Sevion Therapeutics (SVON) and Grifols (GRFS)Head-To-Head Analysis: Sevion Therapeutics (SVON) and Grifols (GRFS)
www.americanbankingnews.com - December 2 at 7:18 PM
Head-To-Head Comparison: Grifols (GRFS) and Jazz Pharmaceuticals (JAZZ)Head-To-Head Comparison: Grifols (GRFS) and Jazz Pharmaceuticals (JAZZ)
www.americanbankingnews.com - November 29 at 9:08 AM
Grifols, S.A. (GRFS) Downgraded by UBS AGGrifols, S.A. (GRFS) Downgraded by UBS AG
www.americanbankingnews.com - November 24 at 11:18 AM
Financial Analysis: Grifols, (GRFS) vs. Osiris Therapeutics (OSIR)Financial Analysis: Grifols, (GRFS) vs. Osiris Therapeutics (OSIR)
www.americanbankingnews.com - November 23 at 11:18 PM
Grifols, S.A. (GRFS) Receives Average Recommendation of "Hold" from AnalystsGrifols, S.A. (GRFS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 21 at 3:52 AM
ETFs with exposure to Grifols SA : November 16, 2017ETFs with exposure to Grifols SA : November 16, 2017
finance.yahoo.com - November 16 at 2:52 PM
$0.29 Earnings Per Share Expected for Grifols, S.A. (GRFS) This Quarter$0.29 Earnings Per Share Expected for Grifols, S.A. (GRFS) This Quarter
www.americanbankingnews.com - November 7 at 5:40 PM
William Blair Analysts Reduce Earnings Estimates for Grifols, S.A. (GRFS)William Blair Analysts Reduce Earnings Estimates for Grifols, S.A. (GRFS)
www.americanbankingnews.com - November 6 at 5:24 AM
Visit To Grifols Headquarters During Tumultuous Time In Catalonia - Seeking AlphaVisit To Grifols' Headquarters During Tumultuous Time In Catalonia - Seeking Alpha
seekingalpha.com - November 3 at 9:09 PM
ETFs with exposure to Grifols SA : November 2, 2017ETFs with exposure to Grifols SA : November 2, 2017
finance.yahoo.com - November 2 at 10:32 PM
Stocks Showing Rising Market Leadership: Grifols Earns 83 RS RatingStocks Showing Rising Market Leadership: Grifols Earns 83 RS Rating
finance.yahoo.com - October 31 at 8:39 PM
Grifols, S.A. (GRFS) Given Consensus Rating of "Hold" by BrokeragesGrifols, S.A. (GRFS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 27 at 3:28 AM
Grifols, (GRFS) vs. ContraFect Corporation (CFRX) Head to Head ComparisonGrifols, (GRFS) vs. ContraFect Corporation (CFRX) Head to Head Comparison
www.americanbankingnews.com - October 24 at 2:14 PM
ETFs with exposure to Grifols SA : October 23, 2017ETFs with exposure to Grifols SA : October 23, 2017
finance.yahoo.com - October 23 at 6:55 PM
Cubist Pharmaceuticals (CBST) & Grifols, (GRFS) Critical ReviewCubist Pharmaceuticals (CBST) & Grifols, (GRFS) Critical Review
www.americanbankingnews.com - October 22 at 6:22 AM
ContraFect Corporation (CFRX) & Grifols, (GRFS) Head to Head ContrastContraFect Corporation (CFRX) & Grifols, (GRFS) Head to Head Contrast
www.americanbankingnews.com - October 19 at 9:07 AM
ETFs with exposure to Grifols SA : October 10, 2017ETFs with exposure to Grifols SA : October 10, 2017
finance.yahoo.com - October 10 at 4:53 PM
Grifols SA :GRFS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017Grifols SA :GRFS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017
finance.yahoo.com - October 9 at 7:22 PM
Grifols, (GRFS) versus Its Peers Financial ReviewGrifols, (GRFS) versus Its Peers Financial Review
www.americanbankingnews.com - October 9 at 4:12 PM
FACTBOX-Companies with big business operations in CataloniaFACTBOX-Companies with big business operations in Catalonia
www.cnbc.com - October 7 at 6:03 AM
Grifols, S.A. (GRFS) Given Consensus Recommendation of "Hold" by AnalystsGrifols, S.A. (GRFS) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - October 2 at 12:44 AM
Aradigm: Hidden Binary Event Or Russian Roulette (With The FDA Spinning The Cylinder)?Aradigm: Hidden Binary Event Or Russian Roulette (With The FDA Spinning The Cylinder)?
seekingalpha.com - September 29 at 4:34 PM
Grifols, (GRFS) vs. Its Peers Head-To-Head AnalysisGrifols, (GRFS) vs. Its Peers Head-To-Head Analysis
www.americanbankingnews.com - September 28 at 6:16 PM
Grifols, (GRFS) versus Its Rivals Critical ComparisonGrifols, (GRFS) versus Its Rivals Critical Comparison
www.americanbankingnews.com - September 27 at 2:06 AM
Cubist Pharmaceuticals (CBST) and Grifols, (GRFS) Critical ContrastCubist Pharmaceuticals (CBST) and Grifols, (GRFS) Critical Contrast
www.americanbankingnews.com - September 25 at 6:32 AM
Head to Head Survey: Idenix Pharmaceuticals (IDIX) & Grifols, (GRFS)Head to Head Survey: Idenix Pharmaceuticals (IDIX) & Grifols, (GRFS)
www.americanbankingnews.com - September 23 at 12:40 PM
Aradigm: Hidden Binary Event Or Russian Roulette (With The FDA Spinning The Chamber)?Aradigm: Hidden Binary Event Or Russian Roulette (With The FDA Spinning The Chamber)?
seekingalpha.com - September 22 at 6:51 PM

SEC Filings

Grifols SA, Barcelona (NASDAQ:GRFS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Grifols SA, Barcelona (NASDAQ:GRFS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Grifols SA, Barcelona (NASDAQ GRFS) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.